Health Care News and Research

RSS

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

10 Dec 2014

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study led by researchers from Boston Children's Hospital, The Children's Hospital at Montefiore, and Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

10 Dec 2014

Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

The use of hypofractionated whole-breast irradiation (HF-WBI) for patients with early-stage breast cancer increased 17.4 percent from 2004 to 2011, and patients are more likely to receive HF-WBI compared to conventionally fractionated whole-breast irradiation (CF-WBI) when they are treated at an academic center or live ≥50 miles away from a cancer center, according to a study published in the December 1, 2014 issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology.

10 Dec 2014

University of Chicago Medicine takes steps to increase age limit of pediatric trauma program

The University of Chicago Medicine is taking formal steps to raise the age limit of its pediatric trauma program by two years to include 16- and 17-year-old children.

10 Dec 2014

Study evaluates effect of 2011 ACGME duty hour reforms on patient outcomes

In the first year after the Accreditation Council for Graduate Medical Education (ACGME) reduced the number of continuous hours that residents can work, there was no change in the rate of death or readmission among hospitalized Medicare patients, according to a new study published in JAMA.

10 Dec 2014

Mayo Clinic, Techstars collaborate to offer new Techstars++ program to health care entrepreneurs

Mayo Clinic announced today a new collaboration with Techstars to offer the Techstars++ program. The Techstars++ program will bring together health care entrepreneurs and companies with Mayo Clinic to find innovative solutions to improve patient care at an accelerated pace.

10 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

10 Dec 2014

Drug proves effective at inhibiting growth of drug-resistant bacteria

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes.

10 Dec 2014

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics, today announced that its Simplexa Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter.

From Quest Diagnostics 9 Dec 2014

Banner Health chooses Craneware's Chargemaster Corporate Toolkit to support ongoing growth

With healthcare consolidation on the rise, Craneware, Inc., the healthcare market leader in automated revenue integrity solutions, today announced that Banner Health, one of the largest not-for-profit healthcare systems in the US, has selected Craneware's Chargemaster Corporate Toolkit to support its ongoing growth and efficient integration across newly acquired facilities.

9 Dec 2014

Good first aid kit can help make your vacation perfect

Planning a vacation? Make a little room in your luggage for a travel first aid kit. It won't cost much, and it won't take up much space. Once you reach your destination, you won't need to reach any further than your suitcase to relieve those minor aches and pains that can put a major damper on your plans.

9 Dec 2014

Highly-paid doctors make more money by ordering multiple procedures for patients: UCLA

In results characterized as "very surprising," UCLA researchers found for the first time that higher-earning clinicians make more money by ordering more procedures and services per patient rather than by seeing more patients, which may not be in patients' best interest.

9 Dec 2014

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Nine in 10 primary care physicians say that prescription drug abuse is a moderate or big problem in their communities and nearly half say they are less likely to prescribe opioids to treat pain compared to a year ago, new Johns Hopkins Bloomberg School of Public Health research suggests.

9 Dec 2014

Case Western Reserve selected to lead $27.3 million international effort to identify causes of SUDEP

Case Western Reserve is one of two universities in the country selected to lead a $27.3 million international effort to identify the causes of a mysterious and deadly phenomenon that strikes people with epilepsy without warning.

9 Dec 2014

Study points to need for improving pediatric benefits under the Affordable Care Act

An article published in the Health Affairs December issue is the first ever comprehensive analysis to investigate the Affordable Care Act's (ACA) Essential Health Benefit (EHB) as it relates to children. The study found that the EHB has resulted in a state-by-state patchwork of coverage for children and adolescents that has significant exclusions, particularly for children with developmental disabilities and other special health care needs.

9 Dec 2014

Adverse childhood experiences impact child health, school outcomes

Nearly half of all children in the United States are exposed to at least one social or family experience that can lead to traumatic stress and impact their healthy development - be it having their parents divorce, a parent die or living with someone who abuses alcohol or drugs - increasing the risk of negative long-term health consequences or of falling behind in school, suggests new research led by the Johns Hopkins Bloomberg School of Public Health.

9 Dec 2014

Children living in non-redeveloped public housing more likely to take repeated trips to emergency rooms

San Francisco children living in non-redeveloped public housing are 39 percent more likely to repeatedly visit emergency rooms, according to new research from UC San Francisco and UC Berkeley.

9 Dec 2014

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Aiming to empower planners and policy-makers to achieve better health for billions of people living in fast-growing urban areas, world health, environmental, behavioural and social science experts today launched a major new interdisciplinary scientific collaboration.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Health Care News and Research

Mylan announces U.S. launch of Celecoxib Capsules

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Use of HF-WBI for patients with early-stage breast cancer increases 17.4%, study finds

University of Chicago Medicine takes steps to increase age limit of pediatric trauma program

Study evaluates effect of 2011 ACGME duty hour reforms on patient outcomes

Mayo Clinic, Techstars collaborate to offer new Techstars++ program to health care entrepreneurs

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Drug proves effective at inhibiting growth of drug-resistant bacteria

Focus Diagnostics' Simplexa Flu A/B & RSV Direct Kit receive FDA clearance

Banner Health chooses Craneware's Chargemaster Corporate Toolkit to support ongoing growth

Good first aid kit can help make your vacation perfect

Highly-paid doctors make more money by ordering multiple procedures for patients: UCLA

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Case Western Reserve selected to lead $27.3 million international effort to identify causes of SUDEP

Study points to need for improving pediatric benefits under the Affordable Care Act

Adverse childhood experiences impact child health, school outcomes

Children living in non-redeveloped public housing more likely to take repeated trips to emergency rooms

Experts launch new interdisciplinary scientific collaboration to improve health in urban areas

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Event guide: 3rd Measuring Patient Engagement Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News